Eli Lilly's Zepbound KwikPen Receives FDA Approval for Obesity Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2024
0mins
Should l Buy LLY?
Source: Benzinga
Eli Lilly's stock rose by 5.00% as it crossed above the 5-day SMA, reflecting positive market activity despite broader market declines.
The catalyst for this movement is the recent FDA approval for a label expansion of Zepbound, allowing the use of a four-dose single-patient use KwikPen. This innovation enhances patient convenience and is expected to significantly boost sales, as evidenced by the drug's strong performance in the SURMOUNT-5 trial, where patients lost an average of 50 pounds. The approval is anticipated to solidify Eli Lilly's position in the obesity treatment market, which has seen explosive demand.
This development not only highlights Eli Lilly's commitment to improving patient care but also positions the company favorably against competitors in the obesity treatment sector, potentially leading to increased market share and revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1051.990
Low
950.00
Averages
1192
High
1500
Current: 1051.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Approaches $1 Trillion Valuation
- Price Target Analysis: Analysts currently project Eli Lilly's price target to be just under $1,230, indicating approximately 17% upside from its current price of $1,031.79, which presents a potential return opportunity for investors.
- Growth Drivers: The strong growth of Eli Lilly's GLP-1 drugs, Zepbound and Mounjaro, has fueled bullish sentiment, as investors grow confident in the company's potential to dominate the anti-obesity drug market, thereby continuing to drive the stock's rally.
- Valuation Considerations: Despite Eli Lilly's market cap nearing $1 trillion, its price-to-earnings ratio stands at 46, significantly higher than the S&P 500 average of 25, suggesting that much of the future growth is already priced in, which could lead to correction risks if expectations are not met.
- Long-term Investment Advice: For long-term investors, Eli Lilly remains a solid investment option, but it is crucial to temper expectations to avoid overestimating future gains, especially given the current high valuation context.
See More
CrowdStrike and Eli Lilly Options Trading Active
- CrowdStrike Options Volume: As of now, CrowdStrike Holdings Inc (CRWD) options have reached a trading volume of 25,887 contracts, equivalent to approximately 2.6 million shares, representing a significant 53.7% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Options Activity: Within CRWD, the $400 strike call option has been particularly active, with 1,316 contracts traded today, representing about 131,600 underlying shares, reflecting investor expectations for future price increases.
- Eli Lilly Options Volume: Concurrently, Eli Lilly (LLY) options have shown a trading volume of 19,886 contracts, approximately 2.0 million shares, accounting for 52.5% of its average daily trading volume over the past month, highlighting the stock's market activity.
- High Strike Options Focus: For LLY, the $1100 strike call option has also been notably active, with 1,461 contracts traded today, representing around 146,100 shares, indicating optimistic sentiment among investors regarding the stock's future performance.
See More
Eli Lilly Achieves $1 Trillion Valuation, Remarkable Returns Over a Decade
- Innovation-Driven Growth: Eli Lilly has achieved remarkable returns over the past decade, becoming the largest healthcare stock globally and the first to surpass a $1 trillion valuation, showcasing its leadership in the industry through significant breakthroughs in diabetes and weight management.
- Diversification Strategy: While diabetes drugs are currently the main growth driver, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product portfolio, thereby ensuring long-term business stability and growth potential.
- Technological Investment Outlook: Lilly's partnership with Nvidia aims to create the pharmaceutical industry's most powerful AI supercomputer and establish a research lab, focusing on accelerating the discovery and development of breakthrough therapies, which, although may not yield immediate returns, lays a solid foundation for the future.
- Attractive Dividend Policy: Having more than doubled its dividends in the past five years, Lilly demonstrates strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its core position in a diversified investment portfolio.
See More
Eli Lilly's Innovations and Dividend Growth Outlook
- Innovation-Driven Growth: Eli Lilly has achieved significant breakthroughs in diabetes and weight management, propelling it to become the largest healthcare stock globally and the first to reach a $1 trillion valuation, showcasing its strong market position and future growth potential.
- Diversification Strategy: While currently relying on the success of tirzepatide, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product lineup, thereby enhancing its long-term competitiveness.
- Technology Investment: Lilly is partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer and research lab, aimed at accelerating the discovery and development of breakthrough therapies; these investments may not yield immediate results but lay a solid foundation for the future.
- Dividend Growth: Over the past five years, Lilly has more than doubled its dividends, reflecting its strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its position as a core holding in investment portfolios.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
Novo Nordisk Stock Plummets 60% Amidst Concerns
- Stock Price Decline: Novo Nordisk's stock has plummeted approximately 60% over the past year, indicating investor concerns about its long-term prospects, particularly in light of competition from Eli Lilly.
- Sales Guidance Downgrade: The company anticipates a decline in adjusted sales of at least 5%, potentially as much as 13%, which is alarming for growth investors and has contributed to the recent sell-off in its stock.
- Legal Action Impact: Novo Nordisk is suing Hims & Hers Health for selling unauthorized versions of its drugs, and if successful in curbing these sales, it could help stabilize its growth rate this year.
- Market Potential Remains: Despite current challenges, Novo Nordisk remains a significant player in the GLP-1 drug market, which is projected to exceed $150 billion by 2035, suggesting that long-term investors may find the current low price-to-earnings ratio appealing.
See More
Eli Lilly Approaches $1 Trillion Valuation
- Price Target Analysis: Analysts currently project Eli Lilly's price target to be just under $1,230, indicating approximately 17% upside from its current price of $1,031.79, which presents a potential return opportunity for investors.
- Growth Drivers: The strong growth of Eli Lilly's GLP-1 drugs, Zepbound and Mounjaro, has fueled bullish sentiment, as investors grow confident in the company's potential to dominate the anti-obesity drug market, thereby continuing to drive the stock's rally.
- Valuation Considerations: Despite Eli Lilly's market cap nearing $1 trillion, its price-to-earnings ratio stands at 46, significantly higher than the S&P 500 average of 25, suggesting that much of the future growth is already priced in, which could lead to correction risks if expectations are not met.
- Long-term Investment Advice: For long-term investors, Eli Lilly remains a solid investment option, but it is crucial to temper expectations to avoid overestimating future gains, especially given the current high valuation context.
See More
CrowdStrike and Eli Lilly Options Trading Active
- CrowdStrike Options Volume: As of now, CrowdStrike Holdings Inc (CRWD) options have reached a trading volume of 25,887 contracts, equivalent to approximately 2.6 million shares, representing a significant 53.7% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Options Activity: Within CRWD, the $400 strike call option has been particularly active, with 1,316 contracts traded today, representing about 131,600 underlying shares, reflecting investor expectations for future price increases.
- Eli Lilly Options Volume: Concurrently, Eli Lilly (LLY) options have shown a trading volume of 19,886 contracts, approximately 2.0 million shares, accounting for 52.5% of its average daily trading volume over the past month, highlighting the stock's market activity.
- High Strike Options Focus: For LLY, the $1100 strike call option has also been notably active, with 1,461 contracts traded today, representing around 146,100 shares, indicating optimistic sentiment among investors regarding the stock's future performance.
See More
Eli Lilly Achieves $1 Trillion Valuation, Remarkable Returns Over a Decade
- Innovation-Driven Growth: Eli Lilly has achieved remarkable returns over the past decade, becoming the largest healthcare stock globally and the first to surpass a $1 trillion valuation, showcasing its leadership in the industry through significant breakthroughs in diabetes and weight management.
- Diversification Strategy: While diabetes drugs are currently the main growth driver, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product portfolio, thereby ensuring long-term business stability and growth potential.
- Technological Investment Outlook: Lilly's partnership with Nvidia aims to create the pharmaceutical industry's most powerful AI supercomputer and establish a research lab, focusing on accelerating the discovery and development of breakthrough therapies, which, although may not yield immediate returns, lays a solid foundation for the future.
- Attractive Dividend Policy: Having more than doubled its dividends in the past five years, Lilly demonstrates strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its core position in a diversified investment portfolio.
See More
Eli Lilly's Innovations and Dividend Growth Outlook
- Innovation-Driven Growth: Eli Lilly has achieved significant breakthroughs in diabetes and weight management, propelling it to become the largest healthcare stock globally and the first to reach a $1 trillion valuation, showcasing its strong market position and future growth potential.
- Diversification Strategy: While currently relying on the success of tirzepatide, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product lineup, thereby enhancing its long-term competitiveness.
- Technology Investment: Lilly is partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer and research lab, aimed at accelerating the discovery and development of breakthrough therapies; these investments may not yield immediate results but lay a solid foundation for the future.
- Dividend Growth: Over the past five years, Lilly has more than doubled its dividends, reflecting its strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its position as a core holding in investment portfolios.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
Novo Nordisk Stock Plummets 60% Amidst Concerns
- Stock Price Decline: Novo Nordisk's stock has plummeted approximately 60% over the past year, indicating investor concerns about its long-term prospects, particularly in light of competition from Eli Lilly.
- Sales Guidance Downgrade: The company anticipates a decline in adjusted sales of at least 5%, potentially as much as 13%, which is alarming for growth investors and has contributed to the recent sell-off in its stock.
- Legal Action Impact: Novo Nordisk is suing Hims & Hers Health for selling unauthorized versions of its drugs, and if successful in curbing these sales, it could help stabilize its growth rate this year.
- Market Potential Remains: Despite current challenges, Novo Nordisk remains a significant player in the GLP-1 drug market, which is projected to exceed $150 billion by 2035, suggesting that long-term investors may find the current low price-to-earnings ratio appealing.
See More
